Tabulation of myeloid, lymphoid and intestinal malignancies in Crohn's disease

Canadian Journal of Gastroenterology

Volumn 16, Issue 11, 2002, Pages 779-784

  Freeman, Hugh J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Colon cancer; Crohn's disease; Immunosuppressives; Infliximab; Leukemia; Multiple myeloma; Small intestinal cancer

Indexed keywords

ALICAFORSEN; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BIOLOGICAL FACTOR; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CLINICAL PRACTICE; COHORT ANALYSIS; COLON CANCER; COLON RESECTION; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DRUG USE; DYSPLASIA; ENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CANCER; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECTUM SURGERY; RISK FACTOR; SEX DIFFERENCE;

EID: 0036869946     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/193285     Document Type: Article

References (38)

1. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn's disease and cancer. N Engl J Med 1973;289:1099-103.
2. Gyde SN, Prior P, MacCartney JC, Thompson H, Waterhouse JAH, Allan RN. Malignancy in Crohn's disease. Gut 1980;21:1024-9.
3. Freeman HJ. Neoplastic complications of inflammatory bowel disease. In: Freeman HJ, ed. Inflammatory Bowel Disease, vol 2. Boca Raton: CRC Press, 1989:23-5.
4. Freeman HJ. Colorectal cancer complicating Crohn's disease. Can J Gastroenterol 2001;15:231-6.
5. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease. A population-based study. Cancer 2001;91:854-62.
6. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;15:2914-21.
7. Hanauer SB, Wong KK, Frank PH, Sweet DL, Kirsner JB. Acute leukemia following inflammatory bowel disease. Dig Dis Sci 1982;27:545-8.
8. Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature. Dig Dis Sci 1986;31:1025-31.
9. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
10. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
11. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
12. Age-standardized incidence rates for cancer, BC Cancer Statistics, Annual Reports, 1991-2000. Vancouver: BC Cancer Agency.
13. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:514-9.
14. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 2000;24:66-73.
15. Minami A, Iwai A, Watanabe Y, et al. Two cases of inflammatory bowel disease with multiple myeloma. J Gastroenterol 1999;34:629-33.
16. Hara T, Ozaki S, Kosaka M, et al. Biclonal lymphoplamacytic immunocytoma associated with Crohn's disease. Intern Med 1999;38:500-3.
17. Freeman HJ. Application of the Vienna Classification for Crohn's disease to a single clinician database of 877 patients. Can J Gastroenterol 2001;15:89-93.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989:170(Suppl):2-6.
19. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
20. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
21. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42.
22. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-82.
23. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
24. Harewood GC, Loftus EV, Tefferi A, Tremaine WJ, Sandborn WJ. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis 1999;5:98-103.
25. Freeman HJ, Weinstein WM, Shnitka TK, Piercey JR, Wensel RH. Primary abdominal lymphoma. Presenting manifestation of celiac disease or complicating dermatitis herpetiformis. Am J Med 1977;63:585-94.
26. Freeman HJ, Chiu BK. Multifocal small bowel lymphoma and latent celiac sprue. Gastroenterology 1986;90:1992-7.
27. Freeman HJ, Chiu BK. Small bowel malignant lymphoma complicating celiac sprue and the mesenteric lymph node cavitation syndrome. Gastroenterology 1986;90:2008-12.
28. Freeman HJ. Neoplastic disorders in 100 patients with celiac disease. Can J Gastroenterol 1996;10:163-6.
29. Freeman HJ. Fulminant liver failure with necrotizing foci in the liver, spleen and lymph nodes in celiac disease due to malignant lymphoma. Can J Gastroenterol 1996;10:225-9.
30. Freeman HJ. Mantle cell lymphoma of the gastrointestinal tract (lymphomatous polyposis). Can J Gastroenterol 1996;10:144-8.
31. Freeman HJ, Anderson MD, Gascoyne RD. Clinical, pathologic and molecular genetic findings in small intestinal follicle center cell lymphoma. Can J Gastroenterol 1997;11:31-4.
32. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989;47:293-6.
33. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-92.
34. Asten P, Marrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
35. Yoo KY, Tajima K, Inoue M, et al. Reproductive factors related to the risk of colorectal cancer by subsite: a case-control analysis. Br J Cancer 1999;79:1901-6.
36. Petras RE, Madjlessi SH, Farmer RG. Crohn's disease and intestinal carcinoma. A report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology 1987;93:1307-14.
37. Sigel JE, Petras RE, Lashner BA, Fazio VW, Goldblum JR. Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol 1999;23:651-5.
38. Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-6.